Benzinga | Jan 27, 2022 08:05AM EST

Argus Research Downgrades Teva Pharmaceutical Indus to Hold

Argus Research analyst Jasper Hellweg downgrades Teva Pharmaceutical Indus (NYSE:TEVA) from Buy to Hold.